2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. Insulin Receptor

Insulin Receptor

Insulin Receptor

Related Products

PDF 0.56 MB

Insulin receptor (IR), a phylogenetically ancient tyrosine kinase receptor, is a large cell surface glycoprotein that concentrates insulin at the site of action and also initiates responses to insulin. The receptor is a disulfide-linked oligomer comprised of two alpha and two beta subunits. The insulin receptor exists in two isoforms, IR-A and IR-B, expressed in different relative abundance in the various organs and tissues. The two IR isoforms have similar binding affinity for insulin but different affinity for insulin-like growth factor (IGF)-2 and proinsulin, which are bound by IR-A but not IR-B.

The insulin receptor has a crucial role in controlling glucose homeostasis, regulating lipid, protein and carbohydrate metabolism, and modulating brain neurotransmitter levels. Insulin receptor dysfunction has been associated with many diseases, including diabetes, cancer and Alzheimer's disease.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-118203
    SU4984
    		Inhibitor 99.14%
    SU4984 is a protein tyrosine kinase inhibitor, with an IC50 of 10-20 μM for fibroblast growth factor receptor 1 (FGFR1). SU4984 is also inhibits platelet-derived growth factor receptor, and insulin receptor. SU4984 can be used for the research of cancer.
    SU4984
  • HY-P3247
    [D-Ala2]-GIP (human)
    		Agonist 98.17%
    [D-Ala2]-GIP (human) is a GIP receptor agonist. [D-Ala2]-GIP (human) improves glucose tolerance. [D-Ala2]-GIP (human) shows neuroprotective activity in MPTP-induced Parkinson's disease model. [D-Ala2]-GIP (human) also improves cognitive function and hippocampal synaptic plasticity in obese diabetic rats. [D-Ala2]-GIP (human) can be used for research of type 2 diabetes, Parkinson's disease, etc
    [D-Ala2]-GIP (human)
  • HY-P99665
    Insulin efsitora alfa
    		Agonist 99.80%
    Insulin efsitora alfa (LY-3209590) is a selective agonist of insulin receptor (IR). Insulin efsitora alfa is a fusion protein composed of human IR agonists fused with the crystallizable (Fc) domain of human immunoglobulin G2 (IgG2) fragment, with a molecular weight of 64.1 kDa. Insulin efsitora alfa is well tolerated and has potential applications in diabetes.
    Insulin efsitora alfa
  • HY-P3584A
    (Pro3) GIP, human TFA
    		99.79%
    (Pro3) GIP, human TFA is an efficacious, stable and specific human GIP receptor (hGIPR) full agonist. (Pro3) GIP, human TFA has high binding affinity for human GIPR with Ki/ Kd value of 0.90 nM. (Pro3) GIP, human TFA human can be used for the research of obesity-related diabetes.
    (Pro3) GIP, human TFA
  • HY-P3580A
    Acetyl Gastric Inhibitory Peptide (human) (TFA)
    		99.70%
    Acetyl Gastric Inhibitory Peptide (human) TFA is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) TFA can be used for research of diabetes, insulin resistance and obesity.
    Acetyl Gastric Inhibitory Peptide (human) (TFA)
  • HY-P1156A
    Insulin(cattle/bovine), purity>95%
    		99.94%
    Insulin cattle is a two-chain polypeptide hormone produced in vivo in the pancreatic β cells. Insulin cattle has often been used as growth supplement in culturing cells.
    Insulin(cattle/bovine), purity>95%
  • HY-P99530
    Valanafusp alfa
    		Inhibitor 98.42%
    Valanafusp alfa (AGT-181) is a brain penetrating recombinant fusion protein of a chimeric monoclonal antibody against the human insulin receptor (HIR) and human iduronidase (IDUA). Valanafusp alfa can be used for the research of Mucopolysaccharidosis type I (MPS I) .
    Valanafusp alfa
  • HY-P2093
    S961
    		Antagonist
    S961 is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.
    S961
  • HY-15656S
    Ceritinib-d7
    		Inhibitor 98.00%
    Ceritinib-d7 is a deuterium labeled Ceritinib. Ceritinib is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor[1].
    Ceritinib-d<sub>7</sub>
  • HY-P3584
    (Pro3) GIP, human
    		Agonist 99.79%
    (Pro3) GIP, human ((Pro3) Gastric Inhibitory Peptide, human) is an efficacious, stable and specific human GIP receptor (hGIPR) full agonist. (Pro3) GIP, human has high binding affinity for human GIPR with Ki/ Kd values of 0.90 nM. (Pro3) GIP, human can be used for the research of obesity-related diabetes.
    (Pro3) GIP, human
  • HY-156110
    IGF2BP1-IN-1
    		Inhibitor
    IGF2BP1-IN-1 (Compound A11) is a IGF2BP1 inhibitor and inhibits downstream signaling. IGF2BP1-IN-1 binds to IGF2BP1 protein with a KD value of 2.88 nM. IGF2BP1-IN-1 inhibits cancer cells proliferation (IC50: 9 nM for A549 cell, 34 nM for HCT116). IGF2BP1-IN-1 induces cancer cell apoptosis. GF2BP1-IN-1 inhibits tumor growth in A549 xenograft mouse model.
    IGF2BP1-IN-1
  • HY-P3255
    DA-JC4
    		Agonist
    DA-JC4 is a dual GLP-1/GIP receptor agonist and can be used for the research of neurological disease and insulin signaling pathways.
    DA-JC4
  • HY-P2093A
    S961 TFA
    		Antagonist
    S961 TFA is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.
    S961 TFA
  • HY-P2080C
    GIP (1-30)-Myr
    		Agonist
    GIP (1-30)-Myr is the Myr-modified GIP (1-30), which is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions. GIP (1-30) dose-dependently promotes insulin secretion over the range 10-9-10-6 M.
    GIP (1-30)-Myr
  • HY-50866B
    NVP-AEW541 dihydrochloride
    		Inhibitor
    NVP-AEW541 dihydrochloride (AEW541 dihydrochloride) is an orally active inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with an IC50 value of 0.15 μM. NVP-AEW541 dihydrochloride also inhibits InsR, IC50 with a value of 0.14 μM. NVP-AEW541 dihydrochloride has antitumor activity.
    NVP-AEW541 dihydrochloride
  • HY-142663
    OI338
    		Agonist
    OI338 is an orally available, ultralong-acting insulin analogue.
    OI338
  • HY-P4062
    Insulin peglispro
    Insulin peglispro (BIL) is a basal insulin with a flat, prolonged activity profile. Insulin peglispro can exhibit better glycaemic control compared to conventional insulins.
    Insulin peglispro
  • HY-P3580
    Acetyl Gastric Inhibitory Peptide (human)
    Acetyl Gastric Inhibitory Peptide (human) is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) can be used for research of diabetes, insulin resistance and obesity.
    Acetyl Gastric Inhibitory Peptide (human)
  • HY-W040127
    Peonidin 3-O-glucoside chloride
    Peonidin 3-O-glucoside chloride, an anthocyanin, act as an insulin secretagogue. Peonidin 3-O-glucoside chloride can increase glucose uptake in HepG2 cells. Peonidin 3-O-glucoside chloride has the potential for type-2 diabetes comorbidities research.
    Peonidin 3-O-glucoside chloride
  • HY-P3578
    Gastric Inhibitory Polypeptide (1-30), porcine
    		Modulator
    Gastric Inhibitory Polypeptide (1-30), porcine lacks the C-terminal 12 amino acid residues of natural gastric inhibitory polypeptide (GIP), exhibits biologic activity by potentiating the release of insulin and somatostatin.
    Gastric Inhibitory Polypeptide (1-30), porcine
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity